List of Excipients in Branded Drug TOBRADEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	TOBRADEX	tobramycin and dexamethasone	0065-0647	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	TOBRADEX	tobramycin and dexamethasone	0065-0647	EDETATE DISODIUM
Alcon Laboratories Inc	TOBRADEX	tobramycin and dexamethasone	0065-0647	HYDROXYETHYL CELLULOSE
Alcon Laboratories Inc	TOBRADEX	tobramycin and dexamethasone	0065-0647	SODIUM CHLORIDE
Alcon Laboratories Inc	TOBRADEX	tobramycin and dexamethasone	0065-0647	SODIUM HYDROXIDE
Alcon Laboratories Inc	TOBRADEX	tobramycin and dexamethasone	0065-0647	SODIUM SULFATE
Alcon Laboratories Inc	TOBRADEX	tobramycin and dexamethasone	0065-0647	SULFURIC ACID

TOBRADEX Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 9, 2026

TOBRADEX is a combination ophthalmic product containing tobramycin 0.3% and dexamethasone 0.1%. Its commercial position depends less on active-ingredient exclusivity than on formulation performance, brand recognition, physician familiarity, preservative strategy, and differentiated delivery formats. The main opportunities are preservative-free multidose delivery, improved suspension uniformity, longer ocular residence, unit-dose packaging, and lower-cost generic or private-label products.

The core product is an ophthalmic suspension. TOBRADEX ST uses a modified vehicle designed to improve suspension behavior and ocular retention. These excipient differences create the most relevant product-development and intellectual-property opportunities.

What is TOBRADEX and which dosage forms are marketed?

TOBRADEX combines an aminoglycoside antibiotic with a corticosteroid for steroid-responsive inflammatory ocular conditions in which bacterial infection or the risk of bacterial infection exists. The product is available as an ophthalmic suspension and ophthalmic ointment. TOBRADEX ST is a higher-viscosity suspension formulation.

Product	Active ingredients	Dosage form	Primary formulation issue
TOBRADEX ophthalmic suspension	Tobramycin 0.3%; dexamethasone 0.1%	Multidose suspension	Redispersibility, preservative exposure, ocular residence
TOBRADEX ophthalmic ointment	Tobramycin 0.3%; dexamethasone 0.1%	Ophthalmic ointment	Blurred vision, patient acceptability, nighttime use
TOBRADEX ST	Tobramycin 0.3%; dexamethasone 0.05%	Higher-viscosity suspension	Retention, dosing convenience, suspension stability

TOBRADEX is an Alcon product. The original product’s commercial value is supported by prescribing familiarity and the clinical utility of combining antibacterial and anti-inflammatory treatment in one bottle. FDA labeling states that the suspension should be shaken well before use and that the products contain benzalkonium chloride as a preservative [1-3].

What excipients are used in TOBRADEX formulations?

The conventional TOBRADEX suspension uses a vehicle containing viscosity, wetting, buffering, tonicity, chelation, and preservation components. The exact inactive-ingredient profile varies by dosage form and product version.

TOBRADEX ophthalmic suspension excipients

The labeled inactive ingredients include:

• Benzalkonium chloride
• Edetate disodium
• Hydroxyethylcellulose
• Sodium chloride
• Sodium sulfate
• Tyloxapol
• Sulfuric acid and/or sodium hydroxide for pH adjustment
• Purified water

The functional architecture is straightforward:

Excipient class	Likely formulation role
Benzalkonium chloride	Antimicrobial preservation
Edetate disodium	Chelation and preservative-support activity
Hydroxyethylcellulose	Viscosity increase and particle suspension
Tyloxapol	Wetting and dispersion of hydrophobic drug particles
Sodium chloride and sodium sulfate	Tonicity and ionic-strength adjustment
Acids and bases	pH control
Purified water	Aqueous vehicle

The combination of hydroxyethylcellulose and tyloxapol is important. Tobramycin sulfate is water soluble, while dexamethasone is poorly water soluble and must be maintained as dispersed particles. The vehicle must prevent rapid settling, allow redispersion after shaking, and avoid excessive viscosity that would impair drop formation.

TOBRADEX ointment excipients

The ointment formulation uses a hydrocarbon base, generally mineral oil and white petrolatum, with a preservative component such as anhydrous chlorobutanol. The ointment offers longer ocular contact time than an aqueous drop but can cause transient blurred vision and may be less acceptable for daytime use [2].

How does TOBRADEX ST differ from conventional TOBRADEX?

TOBRADEX ST uses a xanthan-gum-based vehicle rather than relying primarily on hydroxyethylcellulose. The formulation is designed to increase viscosity and improve ocular residence while maintaining acceptable drop delivery and redispersion.

The principal commercial differences are:

Attribute	TOBRADEX suspension	TOBRADEX ST
Vehicle emphasis	Hydroxyethylcellulose and surfactant dispersion	Xanthan-gum viscosity system
Dexamethasone concentration	0.1%	0.05%
Ocular residence	Conventional	Intended to be improved
Patient-use issue	Shaking and frequent dosing	Higher viscosity and product handling
Differentiation	Established reference product	Reformulated branded product

A formulation strategy based on xanthan gum can increase retention on the ocular surface and reduce drainage through the nasolacrimal system. The development challenge is balancing residence time against visual blur, drop size, bottle expressibility, microbial protection, and suspension uniformity.

What excipient strategy has the strongest commercial potential?

The strongest opportunities are not simple substitution of one thickener for another. They involve integrated delivery systems that address preservative toxicity, dosing frequency, handling, and manufacturing robustness.

Preservative-free TOBRADEX

Benzalkonium chloride is effective and widely used, but repeated exposure can damage the ocular surface, particularly in patients with dry eye, chronic inflammation, glaucoma, or frequent topical dosing. A preservative-free version could target postoperative and ocular-surface-sensitive patients.

Potential technologies include:

• Unit-dose blow-fill-seal packaging
• Multidose bottles with one-way valves
• Preservative-free pump systems
• Alternative preservation systems with lower ocular-surface burden
• Low-water-activity or antimicrobial container-closure designs

A preservative-free product would require microbiological challenge testing, container-closure validation, extractables and leachables work, and stability testing under in-use conditions. The packaging system may provide more defensible intellectual property than the active ingredients.

Improved suspension systems

Dexamethasone particle size, crystal habit, surface treatment, and wetting behavior directly affect dose uniformity and redispersion. A differentiated suspension may use:

• Micronized dexamethasone
• Controlled particle-size distribution
• Surface-modified particles
• Polymer-surfactant combinations
• Structured vehicles with reduced sedimentation
• In situ gelling systems

The best commercial profile would combine rapid redispersion with low shaking force and consistent delivered dose throughout bottle life.

Ocular in situ gels

A low-viscosity drop that increases viscosity after contact with the tear film could improve residence without making the bottle difficult to use. Candidate mechanisms include ion-activated, temperature-sensitive, or pH-responsive gels.

The main development risks are blurred vision, variable gelation across patients, bottle clogging, and dose nonuniformity. A gel platform may support a 505(b)(2) development path if the formulation changes are substantial but the active ingredients and clinical use remain closely related to the reference product.

Unit-dose packaging

Unit-dose packaging can remove benzalkonium chloride and improve sterility control. It is attractive for surgical centers, hospitals, and postoperative regimens where short treatment courses justify higher packaging cost.

Commercial disadvantages include higher material consumption, greater packaging-line complexity, and increased shipping volume. Unit-dose products may compete effectively where preservative avoidance or institutional purchasing is more important than the lowest retail price.

What formulation patents could protect a TOBRADEX follow-on product?

Formulation patents could cover the interaction between the active ingredients, excipients, packaging, and delivery method. The strongest claims would usually require more than naming a known excipient.

Potential claim categories include:

Patent category	Potential protected subject matter
Composition	Specific polymer, surfactant, buffer, and tonicity ranges
Particle engineering	Dexamethasone particle size, morphology, or surface treatment
Suspension stability	Sedimentation rate, redispersion time, or dose uniformity
Preservative-free delivery	Multidose container and microbial-control system
In situ gel	Triggered viscosity increase after administration
Container closure	Valve, pump, unit-dose ampule, or bottle architecture
Manufacturing	Milling, homogenization, sterilization, or aseptic filling process
Method of use	Reduced dosing frequency or improved treatment of defined patient subgroups

An excipient patent is stronger when it ties composition to a measurable technical result, such as improved redispersion, lower particle settling, reduced preservative exposure, or sustained ocular residence. A claim covering only “tobramycin, dexamethasone, and xanthan gum” may face prior-art and obviousness pressure if the components and ranges are conventional.

What is the Orange Book and regulatory status of TOBRADEX?

TOBRADEX is an FDA-approved ophthalmic drug product. The relevant regulatory pathway depends on the proposed product:

• An ANDA may be appropriate for a therapeutically equivalent generic suspension or ointment.
• A 505(b)(2) application may be appropriate for a materially different vehicle, dosage form, preservative system, dosing regimen, or delivery device.
• A new drug application may be required where the product has a new clinical claim or insufficient reliance on the reference product.

The FDA Orange Book identifies approved products, applicants, therapeutic-equivalence ratings, and listed patent or exclusivity information where applicable [4]. Commercial diligence should distinguish the original TOBRADEX product from TOBRADEX ST because separate applications, labeling, formulations, and regulatory histories can affect the pathway.

For established products of this age, the principal barrier is unlikely to be new chemical-entity exclusivity. The relevant risks are formulation patents, regulatory exclusivity, reference-product requirements, ANDA suitability, and litigation based on listed patents. An Orange Book search should be performed by exact application number and product name before launch planning.

When does TOBRADEX lose exclusivity?

TOBRADEX’s active ingredients are old, and conventional composition-of-matter exclusivity is not the principal commercial issue. Any original drug exclusivity and early formulation patents would generally have expired or become commercially weak by the current market period. Later reformulations, including TOBRADEX ST, must be assessed separately.

The practical exclusivity timeline is:

Exclusivity layer	Commercial relevance
Active-ingredient exclusivity	Minimal for tobramycin/dexamethasone
Original formulation patents	Generally historical for the legacy product
Reformulation patents	Potentially relevant for vehicle or delivery differences
Regulatory exclusivity	Depends on the specific FDA application and approval history
Trademark and brand equity	Remains commercially relevant
Trade secrets	May protect manufacturing parameters and process controls

No reliable product-level revenue figure is publicly disclosed for TOBRADEX in standard SEC filings. Revenue exposure should therefore be modeled using prescription volume, wholesale acquisition price, payer mix, generic substitution, and the share attributable to TOBRADEX ST rather than relying on a reported brand figure.

Which companies are challenging or competing with TOBRADEX?

Competition comes from several groups:

1. Generic manufacturers selling tobramycin/dexamethasone ophthalmic suspension or ointment.
2. Branded ophthalmic companies offering competing antibiotic-steroid combinations.
3. Manufacturers of tobramycin or dexamethasone monotherapy.
4. Postoperative ophthalmic companies offering newer steroid vehicles or fixed-dose combinations.
5. Compounding pharmacies supplying customized preservative-free products in selected markets.

The most direct generic threat is a therapeutically equivalent suspension with lower acquisition cost. A reformulated product can reduce substitution if it has a distinct formulation, delivery system, or regulatory status, but brand differentiation must be clinically meaningful or supported by contracting.

What generic launch scenarios exist for TOBRADEX?

Scenario 1: Conventional generic suspension

This is the lowest-cost and most direct strategy. The product would compete on price, pharmacy substitution, hospital contracts, and payer formulary placement. The principal technical requirements are particle-size control, content uniformity, redispersion, sterility, preservative effectiveness, and stability.

Scenario 2: Generic ointment

An ointment can serve nighttime treatment and patients who need longer ocular contact. Manufacturing and filling requirements differ from aqueous suspensions, creating a separate technical barrier.

Scenario 3: Preservative-free product

A preservative-free suspension or gel could command a premium and compete for ocular-surface-sensitive patients. The main investment is in packaging and microbiological control rather than active pharmaceutical ingredient development.

Scenario 4: 505(b)(2) extended-residence product

A higher-viscosity or in situ-gelling product could support a differentiated dosing regimen. This route offers greater commercial upside but requires more clinical and regulatory work than a conventional ANDA.

How strong is the TOBRADEX patent estate?

The legacy active-ingredient estate is weak because both components are long-established drugs. Patent strength is more likely to reside in specific formulation or delivery patents than in the underlying combination.

Estate component	Relative strength
Tobramycin composition patents	Low
Dexamethasone composition patents	Low
Conventional combination formulation	Low to moderate
Xanthan-gum or high-viscosity reformulation	Moderate if claims are narrow and technically supported
Preservative-free packaging	Moderate to strong if device claims are specific
Manufacturing process	Moderate; often protected as trade secret rather than broad patent
Method-of-use claims	Variable and vulnerable to prior art

A follow-on developer should expect Paragraph IV risk only if an active Orange Book-listed patent remains relevant to the targeted product. For a conventional generic, the key litigation question is whether the reference product has current listed patents covering the exact dosage form or formulation. For a 505(b)(2) product, patent certification and possible litigation must be assessed against each relied-upon reference product.

What geographic opportunities exist for TOBRADEX excipients and delivery systems?

The United States offers the most structured generic and 505(b)(2) pathways. Europe and other regulated markets may favor preservative-free multidose systems because of increased attention to ocular-surface tolerability. Emerging markets may favor low-cost suspension or ointment products, where packaging cost and supply reliability are decisive.

Geographic strategy should account for:

• Different approved excipients and concentration limits
• Local preservative expectations
• Pharmacopoeial requirements
• Patent term and status by country
• Device registration requirements
• Cold-chain or stability constraints
• Hospital procurement practices
• Local substitution rules

A single global formulation may not be optimal. A premium preservative-free system may fit Europe and specialty ophthalmology, while a conventional preserved suspension may remain the most competitive product in price-sensitive markets.

Key Takeaways

• TOBRADEX is a tobramycin/dexamethasone ophthalmic product whose differentiation is primarily formulation-based.
• The conventional suspension relies on benzalkonium chloride, hydroxyethylcellulose, tyloxapol, edetate disodium, salts, and purified water.
• TOBRADEX ST uses a higher-viscosity xanthan-gum vehicle and represents the clearest branded reformulation opportunity.
• The most attractive follow-on opportunities are preservative-free packaging, unit-dose delivery, improved suspension redispersion, and in situ-gelling systems.
• Active-ingredient patent protection is weak because tobramycin and dexamethasone are established molecules.
• Formulation patents are strongest when tied to measurable performance, such as dose uniformity, ocular residence, reduced preservative exposure, or improved redispersion.
• Generic suspension and ointment products face lower technical barriers than 505(b)(2) delivery platforms.
• Product-level TOBRADEX revenue is not publicly reported with sufficient specificity for a reliable standalone estimate.
• Orange Book status, patent listings, and Paragraph IV exposure must be reviewed separately for TOBRADEX suspension, ointment, and TOBRADEX ST.
• Manufacturing know-how, container-closure design, and aseptic processing may provide more durable protection than broad excipient claims.

FAQs

Can TOBRADEX be reformulated without benzalkonium chloride?

Yes. A preservative-free version could use unit-dose packaging or a validated multidose container system. The formulation would require new sterility, in-use, container-closure, and stability validation.

Is xanthan gum the main differentiator in TOBRADEX ST?

Xanthan gum is a major vehicle differentiator because it can increase viscosity and ocular residence. Commercial differentiation also depends on particle engineering, redispersion, drop delivery, preservative performance, and clinical labeling.

Would a preservative-free TOBRADEX require an ANDA or 505(b)(2) application?

The pathway depends on the extent of formulation and packaging differences and whether the proposed product can demonstrate therapeutic equivalence to the reference. A materially different delivery system may require a 505(b)(2) approach.

Are excipients in TOBRADEX individually patentable?

Known excipients generally cannot be patented merely because they are used in the product. Patentable subject matter may exist in specific combinations, concentration ranges, particle treatments, delivery systems, manufacturing processes, or demonstrated technical effects.

What is the largest commercial risk for a TOBRADEX generic?

The largest risk is price-driven substitution by established generic manufacturers. A new entrant needs a cost advantage, differentiated preservative strategy, superior packaging, hospital contracts, or a clinically meaningful delivery benefit.

References

1. U.S. Food and Drug Administration. (2023). TOBRADEX ophthalmic suspension prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2023). TOBRADEX ophthalmic ointment prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2023). TOBRADEX ST ophthalmic suspension prescribing information. DailyMed.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

5. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

6. United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. USP-NF.